In fact, an antagonist IL-2 mutein with enhanced binding to IL2Rβ chain but reduced signaling capacity reduced inflammatory response in a mouse GVHD model (282), presumably by displacing and antagonizing the effects of endogenous WT IL-2 on pathogenic cells such as Teff and NK cells. The gene discussed is IL2; the disease is graft versus host disease.